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Background: Telomere length (TL) in circulating leukocytes relates to the chronological age of
the individual but it is believed to reflect also the cumulative burden of oxidative stress
and inflammation over the life-time. Shortening of TL has been reported in several chronic
conditions characterized by oxidative stress and inflammation, such as diabetes and athero-
sclerosis. Because these conditions also occur in patients with Obstructive Sleep Apnea
Syndrome (OSAS), we hypothesized that TL would be reduced in patients with OSAS.
Methods: We compared TL in 256 patients with OSAS and 148 controls without OSAS. We also
investigated if TL was related to the severity of OSAS, the presence of metabolic disorders
and/or cardiovascular risk factors in these patients.
Results: TL was significantly shorter in patients with OSAS than in controls (p< 0.001). This
difference persisted after adjustment for age, body mass index, cholesterol, triglycerides,
glucose, and uric acid levels, smoking status and the presence of arterial hypertension
(pZ 0.018). TL was not related to the severity of OSAS as assessed by the apneaehypopnea
index, nocturnal oxygen saturation and daytime sleepiness.
Conclusions: TL in circulating leukocytes is shorter in patients with OSAS than subjects without
OSAS. The mechanism of this observation is unresolved since it appears independent of chro-
nological age, the severity of OSAS and/or the presence of cardiovascular or metabolicPAR, and Fondo de Investigaciones Sanitarias.
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these patients justifies further studies.
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The obstructive sleep apnea syndrome (OSAS) is often asso-
ciated to cardiovascular disease and metabolic syndrome.1,2
The mechanism(s) underlying these associations is unclear
but oxidative stress and systemic inflammation has been
proposed to explain them.3,4
Telomeres are complex DNA-protein structures located
at the end of eukaryotic chromosomes. They are dynamic
regulators of cellular life span and chromosome integrity.5
Due to inefficient replication, telomere length (TL)
shortens progressively with each division. TL is therefore
considered a marker of cellular ageing.6 Yet, TL shows a high
degree of individual variability in relation to both genetic
and environmental factors.7 Among the latter, oxidative
stress and inflammation are known to accelerate the rate of
telomere attrition. In this context, it has been suggested
that TL of circulating leukocytes reflects the cumulative
burden of the oxidative, inflammatory andmetabolic burden
associated with chronic, age-related diseases such athero-
sclerosis, hypertension, obesity and diabetes.8,9 In fact,
excessive telomere shortening has recently been shown to
occur in circulating leukocytes of many of these age-related
disorders 5,10
Given that oxidative stress, systemic inflammation
and metabolism disturbances occur frequently in OSAS, we
hypothesized that TL would be reduced in these patients. To
test this hypothesis, we compared TL in circulating leuko-
cytes in patients with OSAS and controls of similar chrono-
logical age. To get further insight into potential mechanisms
of TL attrition in OSAS, we investigated the relationship of TL
to the severity of OSAS, the presence of metabolic disorders
and cardiovascular risk factors.
Methods
Subjects and ethics
In this case-control study we included 256 patients with OSAS
and 148 controls. Participants of both sexes were recruited
and studied at sleep unit of our institution. They were
all caucasians. The diagnosis of OSAS was established by
full polysomnography (E-Series Compumedics, Abbotsford,
Australia) and included recording of oronasal flow, thor-
acoabdominal movements, electrocardiography, submental
and pretibial electromyography, electrooculography, elec-
troencefalography and trancutaneous measurement of
arterial oxygen saturation. The case or control status was
defined by the AHI threshold of 10 or greater.
Apnea was defined as the absence of airflow for more
than 10 s.
Hypopnea was defined as an airflow reduction >30% and
<90% that lasted more than 10 s and resulted in arousal or
oxygen desaturation. We considered a desaturation as the
decrease in SaO2 greater 3%. The oxygen desaturation index(ODI) was defined as number of desaturation events per
hour of study time. The apneaehypopnea index (AHI) was
defined as the sum of the number of apneas plus hypopneas
per hour of sleep. OSAS was diagnosed whenever the AHI
was 10 h1 or greater. In controls, the diagnosis of OSAS was
excluded by conventional polysomnography (in subjects
whose BMI was >30 kg/m2) or by a cardiorespiratory sleep
study that recorded nasal flow, thoracic movements, heart
rate, snoring, body position and transcutaneus oxyhemo-
globin saturation (Edentec, MN, USA).
Exclusion criteria (both in cases and controls) were
presence of chronic obstructive pulmonary disease (COPD),
liver cirrhosis, thyroid dysfunction, rheumatoid arthritis,
chronic renal failure and/or psychiatric disorders. Patients
with OSAS were studied before initiating any form of
therapy. Participants taking hypoglycemic and/or antihy-
pertensive agents were considered as diabetic and/or
hypertensive subjects.
The study was approved by the Ethics Committee of our
institution and all participants signed their consent after
being fully informed of its goal and characteristics.
Measurements
Blood samples (10 ml) were obtained between 8 and 10
am after an overnight fast into tubes containing EDTA
and without anticoagulant for biochemical determinations.
After centrifugation serum and plasma were immediately
separated in aliquots and stored at 80 C.
DNA extraction and measurement of leukocyte
telomere length
DNA extraction of each blood sample was made using a DNA
extraction Kit (Wizard Genomic, UK). Leukocyte TL was
measured with a quantitative PCR-based technique that
compares telomere repeat sequence copy number (T ) to
a reference single copy-gene copy number (S ) as previously
described.11 The reference single copy gene used in this
study was human b globin (36b4 gene). All PCRs were done
with the Lightcycler 2.0 (Roche Diagnostics Ltd, Rotkreuz,
Switzerland). The telomere length was expressed as a ratio
of the number of telomere repeats for T runs and the
number of single copy gene copies for S runs (telomere/
single copy gene, referred to as the T/S ratio), with the
mean data from the duplicate runs. All analyses were done
blinded to case-control status of the individual.
Biochemical analysis
Glucose, triglycerides, total cholesterol, HDL cholesterol
(HDLc) and uric acid concentrations were determined by
standard enzymatic methods on a Hitachi Modular analyzer
(Roche Diagnostics, Indianapolis, USA). LDL cholesterol
levels were estimated using the Friedewald equation.
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Telomere length and sleep apnea 1227Statistical analysis
Results are shown as mean SEM. Comparisons between
patients and controls were performed with independent
t-test or ManneWhitney test for normally or not-normally
distributed data respectively.
Correlations between variables were explored using the
Spearman-rank test.
To determine the effect of sleep apnea on TL we used
a multiple regression analysis with study group, age, BMI,
hypertension status, diabetes, cardiovascular disease,
smoking status, pack-years, glucose, triglycerides, choles-
terol and uric acid as the independent variables, and TL
(T/S ratio) as the dependent variable.
Statistical significance was defined as p< 0.05.OSAS CONTROLS
0,80
Figure 1 Box plot of TL in OSAS and controls.Results
Table 1 shows the main clinical characteristics and
biochemical parameters investigated in this study. The
proportion of males and females was similar in both
groups. Age was slightly higher in patients with OSAS, but
differences were not significant. In contrast BMI and the
proportion of current smokers were higher in patients
with OSAS (all p< 0.05). By definition patients with OSAS
showed abnormal sleep parameters and increased somno-
lence (as assessed by the Epworth scale), whereas these
variables were normal in controls. According to the AHI,
OSAS was severe in the patients studied (Table 1). Finally,
systolic and diastolic pressure, glucose, triglycerides and
uric acid levels were higher in patients with OSAS than in
controls, but there were no differences in cholesterol
levels (Table 1).Table 1 Characteristics of patients with OSAS and controls.
OSAS pati
Men, n (%) 212 (82.8)
Age (years) 51 1
BMI (kg/m2) 31.2 0.4
Smoking status, n (%)
Current smokers 85 (33.2%)
Former smokers 73 (28.5%)
Never smokers 98 (38.3%)
SBP (mmHg) 132 1
DBP (mmHg) 82 1
AHI (events/hour) 52 2
Mean Sat O2 (%) 92 1
Min Sat O2 (%) 80 1
Oxygen desaturation index 37 27
Epworth scale 10 1
Glucose (mg/dL) 108 2
Cholesterol (mg/dL) 210 3
HDL cholesterol (mg/dL) 53 1
Triglycerides (mg/dL) 158 8
Uric acid (mg/dL) 6.2 0.1
BMI: body mass index; SBP: systolic blood pressure; DBP: diastoli
**p< 0.001.Telomere length assessed by the average T/S ratio was
significantly shorter in patients with OSAS (0.953 0.070)
than in controls (0.985 0.099) (p< 0.001), (Figure 1). This
difference persisted after adjustment for age, BMI, choles-
terol, triglycerides, glucose, and uric acid levels, smoking
status and hypertension status (pZ 0.018). As shown in
Table 2, when these variables were included as potential
independent variables in the regression analysis, their
presence did not predict the telomere length.
In patients with OSAS, TL was not related to the IAH,
mean Sat O2, min Sat O2, oxygen desaturation index or the
Epworth scale.ents (nZ 256) Controls (nZ 148)
107 (72.8)
47 1
28.3 0.4**
8 (6.1%) **
43 (32.6%)
81 (61.4%)
124 1 **
77 1 **
3 1**
95 1 **
87 2 **
6 7 **
8 1*
95 1 **
211 3
55 1 *
126 6 *
5.6 0.1 **
c blood pressure; AHI: apnea plus hypopnea index. *p< 0.05,
Table 2 Multivariate regression analysis for the association of leukocyte TL in all study subjects.
Unstandardized coefficients
b Standard error Significance
OSAS group 0.029 0.012 0.018
Age 0.000 0.000 0.746
Sex 0.006 0.014 0.683
BMI 0.001 0.001 0.243
Hypertension 0.000 0.000 0.834
Smoking 0.002 0.006 0.796
Glucose 0.000 0.000 0.053
Cholesterol 0.000 0.000 0.570
HDL cholesterol 0.000 0.000 0.618
Triglycerides 0.000 0.000 0.796
Uric acid 0.001 0.004 0.720
1228 A. Barcelo´ et al.Discussion
The main and novel finding of this study is that telomere
length (TL) in circulating leukocytes is shorten in patients
with OSAS than in subjects without the disease (Fig. 1). This
difference appears independent of chronological age and
classical cardiovascular risk factors such as hypertension,
obesity, smoking status, cholesterol, glucose and uric acid
levels (Table 2).
TL reflects the biological age of humans, which may differ
from the chronological age because TL is also influenced by
the cumulative burden of inflammation and oxidative stress
over the individual’s life course.6,7 To our knowledge, no
previous study has investigated TL in patients with OSAS. Yet,
in keeping with our findings, several previous studies have
shown an association between telomere attrition and
atherosclerosis, endothelial dysfunction, diabetes and
cardiovascular mortality all of them highly prevalent among
patients with OSAS.12e15 Also in keeping with our findings,
other studies failed to show an association between TL and
classical cardiovascular factors including cholesterol (total
and fractions), glucose, hypertension, obesity or smoking
status.16 The fact that TL was not related to chronological
age, neither in patients or controls, is likely due to the
narrow age-range observed in both groups.
We did not identify any obvious mechanism that could
explain the difference in TL between OSAS patients and
controls because the AHI, ODI, mean Sat O2, or Epworth scale
were not related to TL in patients with OSAS. On the other
hand, despite that the numeric difference in TL between
patients and controls was small, it remained significant after
adjusting for relevant confounding factors. In any case
controls and patients were drawn from the same clinical
population with lots of risk factors in common and it is the
sleep study that divides the subjects in OSAS and not OSAS.We
propose that the consequences of OSAS, such as oxidative
stress and inflammation, rather OSAS per se, may affect TL.
Unfortunately, we did not determine any oxidative or inflam-
matory marker in these patients. On the other hand, several
studies have shown that a substantial proportion of individual
differences in telomere length is genetically determined.17
Alternatively, it is possible that, once OSAS is established,
other genetic and environmental factors have greater influ-
ence in determining the rate of telomere shortening.An important question is whether TL measured at any
age is simply a marker of the cumulative oxidative and
inflammatory burden through life or, alternatively it plays
an active pathogenic role in predisposition to adverse
outcomes by, for instance, reducing tissue repair.10In this
context, two recent prospective studies have shown that
untreated OSAS is associated with increased mortality even
after controlling for relevant confounders.18,19 Further, the
association between OSAS and mortality was only partly
explained by cardiovascular disease and the mechanisms by
which OSAS contribute to mortality are poor understood.20
In any case, the potential value of the excessive telomere
shortening identified in this study as a biomarker of adverse
outcome in OSAS deserves further investigation.
Two potential limitations of our study deserve comment.
First, as discussed above, we did not evaluate biomarkers
of oxidative stress or inflammation, so we could not
investigate potential relationships between them and TL.
Second, we did not determine the rate of change of TL with
time or the potential effect of treatment of OSAS with
continuous positive airway pressure (CPAP), which may
provide further insights into the significance of telomere
dynamics in OSAS patients.
In summary, telomere length in circulating leukocytes is
shorter in patients with OSAS than subjects without OSAS
and this appears independent of chronological age, hyper-
tension, obesity, smoking status, cholesterol, glucose and
uric acid levels. The precise biological mechanisms linking
OSAS and shortened telomeres, as well as it potential utility
as a biomarker of increased cardiovascular risk in these
patients justify further studies.
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